Type I IL-1 Receptor (IL-1RI) as Potential New Therapeutic Target for Bronchial Asthma

Jyh-Hong Lee, Li-Chieh Wang, Hsin-Hui Yu, Yu-Tsan Lin, Yao-Hsu Yang, and Bor-Luen Chiang

1 Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 100, Taiwan
2 Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan

Correspondence should be addressed to Bor-Luen Chiang, gicmbor@ntu.edu.tw

Received 15 December 2009; Revised 26 March 2010; Accepted 31 May 2010

Academic Editor: Philipp Lepper

Copyright © 2010 Jyh-Hong Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The IL-1R/TLR family has been receiving considerable attention as potential regulators of inflammation through their ability to act as either activators or suppressors of inflammation. Asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness, allergic inflammation, elevated serum total, allergen-specific IgE levels, and increased Th2 cytokine production. The discovery that the IL-1RI–IL-1 and ST2–IL-33 pathways are crucial for allergic inflammation has raised interest in these receptors as potential targets for developing new therapeutic strategies for bronchial asthma. This paper discusses the current use of neutralizing mAb or soluble receptor constructs to deplete cytokines, the use of neutralizing mAb or recombinant receptor antagonists to block cytokine receptors, and gene therapy from experimental studies in asthma. Targeting IL-1RI–IL-1 as well as ST2–IL-33 pathways may promise a disease-modifying approach in the future.

1. Introduction

Asthma is characterized by allergic inflammation of the airways with local infiltration of eosinophils, mast cells, and activated T helper lymphocytes [1]. The initial immune response responsible for this is the generation of allergen-specific CD4+ T helper-2 cells (Th2) that produce Th2 cytokines (IL-4, IL-5, IL-9, and IL-13), but not T helper-1 (Th1) cytokines (IL-2, IL-12, and interferon-γ [IFN-γ]). Overwhelming evidence in literature supports the concept that allergic inflammation is driven by an imbalance between Th1 and Th2 cytokines, favoring the Th2 immune response [1]. IL-4, together with IL-13, is required for Th2-cell development and is intimately involved in the regulation of immunoglobulin E (IgE) production by sensitized allergen-specific B cells, which is a fundamental mechanism in the pathogenesis of allergic asthma [2]. IL-5 is the principal cytokine involved in eosinophil growth, maturation, differentiation, survival, and activation [3, 4]. Cross-linking of allergen-specific IgE on mast cells and the activation of T cells and eosinophils during subsequent encounters with antigens stimulates the release of various preformed and newlysynthesized products, including histamines, cytokines, and chemokines. Together, these lead to characteristic airway changes that contribute to airway obstruction, airway hyperresponsiveness (AHR), goblet cell metaplasia, mucus overproduction, mucosal edema, and airway remodeling [5].

Pulmonary allergic inflammation can be induced in small rodents, such as BALB/c mice, is widely used as an experimental model for human asthma, and is central to the preclinical development of drug therapies [6]. One of the most common murine models of allergen-induced airway inflammation involves mouse sensitization using a small dose of a protein allergen followed by allergen challenge of the airways to induce pulmonary inflammation [7]. This is usually done by injecting the protein intraperitoneally along with an aluminum hydroxide as adjuvant to enhance the protein’s immunogenicity [8]. After the immune system has had a chance to mount a reaction against the antigenic protein (sensitization) over several days, the animal receives further antigen exposure either directly to the lungs in the form of an aerosol or via postnasal drip following nasal instillation (challenge). This characteristically leads to AHR, lung eosinophilia, mucus hypersecretion, and increased IgE


levels, which are all features commonly associated with human allergic asthma [5].

The IL-1 family has been involved in inflammatory and immunologic responses [9]. Members contain activators and suppressors of inflammation [9]. Interleukin-1 receptors (IL-1Rs) and Toll-like receptors (TLRs) are members of a large superfamily of phylogenetically conserved proteins involved in innate immunity and inflammation [10]. The common characteristics of these two receptor families include their presence in the cytoplasmic region of a conserved sequence called Toll/IL-1R (TIR) domain [9, 11]. The IL-1R/TLR-driven immune response also has an essential role in the induction and/or regulation of allergic inflammation and disease exacerbations.

ST2, one member of the IL1 receptor family, was firstly identified as an orphan receptor in 1989 [12]. In 2005, the discovery of interleukin-33 (IL-33) as an ST2 ligand provided new insights into ST2 signalling pathway [13]. ST2/IL-33 signalling is involved in T-cell mediated immune responses, particularly Th2 cells and the production of Th2-associated cytokines [14].

Allergic asthma is used as an example of a chronic inflammatory disease to show how IL-1R/TLR-related pathway offer possibilities of therapeutic intervention. Due to similar roles in the pathogenesis of allergic inflammation, focus was on the IL-1RI-IL-1 and ST2-IL-33 pathways to review their potential as therapeutic targets for treating asthma [15]. Special attention was given to the experimental approach in validating the possibility of targeting IL-1R/TLR to explore emerging treatments.

2. IL-1RI-IL-1

IL-1R was first described and cloned in the family [11, 16–21]. The IL-1R type 1 (IL-1RI) contains three extracellular immunoglobulin (Ig) domains [9, 11]. A second chain, the IL-1 receptor accessory protein (IL-1RAcP) [22] has been reported. It is essential for the signal transduction for IL-1 and IL-33 and is highly homologous to IL-1RI. IL-1RAcP forms a heterodimer with either the IL-1RI or the IL-33Ra chain (ST2) [9]. IL-1RI and IL-1RAcP form the receptor complex for IL-1 (both IL-1α and IL-1β) and binds naturally occurring IL-1 receptor antagonists (IL-1Ra) [23]. The Drosophila protein Toll has a cytosolic domain homologous in sequence to IL-1RI [24], which is called the TIR domain. It is also found in the cytoplasmic domains of each TLR, sometimes shortened to the Toll-IL-1 receptor domain [25]. The TIR domains of IL-1RI and the coreceptor IL-1RAcP are necessary for signal transduction.

2.1. Signaling Pathway. Detailed structures for IL-1 bound to the IL-1RI/IL-1RAcP complex have been discovered, as well as structures for IL-1RA bound to IL-1RI/IL-1RAcP [26, 27]. In crystallization studies, IL-1RI undergoes conformational change when binding IL-1β and allows IL-1RAcP to form the heterodimer [9]. The formation of an IL-1 receptor heterodimer complex results in the approximation of adjacent TIR domains. This complex recruits intracellular adapter molecules, including MyD88 (myeloid differentiation factor 88), IRAK (IL-1R associated kinase), and TRAF6 (tumor necrosis factor [TNF] receptor-associated factor 6), to activate signal transduction pathways such as nuclear factor-κB (NF-κB), AP-1 (activator protein-1), JNK (c-Jun N-terminal kinase), and p38 MAPK (mitogen-associated protein kinase) [21, 28].

In an animal model of asthma, persistent NF-κB activation in the bronchi is driven by granulocytes via IL-1β and TNF-α, which both induce IL-1α degradation, perpetuating the immune response in asthmatic airways [29, 30]. IL-1Ra binds tightly to IL-1RI and blocks the activity of either IL-1α or IL-1β. One of the binding sites of IL-1Ra binds to IL-1RI with high affinity such that the second binding site cannot recruit the IL-1RAcP [9].

2.2. Studies in IL-1RI/IL-1 Pathway-Deficient Mice. The critical role of IL-1RI/IL-1RI in the development of allergic Th2 responses in both mild and more severe asthma has been studied [31]. The role of IL-1 in pulmonary immune responses in models of allergic asthma has been investigated using IL-1R1-deficient (IL-1RI (−/−)) mice. Pulmonary eosinophilic inflammation, goblet cell hyperplasia, priming of CD4+ T cells in bronchial lymph nodes and their recruitment to the lungs, and antibody responses, including IgG, IgE, and IgA, are strongly reduced in IL-1R1 (−/−) compared to control BALB/c mice. In contrast, in a model of more severe asthma, eosinophilic inflammation, antibody responses, and CD4+ T cell priming in lymph nodes are comparable between IL-1R1 (−/−) and wild-type mice. These results suggest an important role of IL-1/IL-1RI in developing allergic Th2 responses, but may not be necessary for severe allergic Th2 responses.

Another study demonstrates that IL-1 plays important roles in the development of AHR by validating IL-1α, IL-1β, and the natural inhibitor of both molecules [32]. It demonstrates that ovalbumin (OVA)-induced AHR, OVA-specific T cell proliferation, IL-4 and IL-5 production by T cells, and IgG1 and IgE production by B cells, in IL-1α/β-deficient [IL-1α (−/−)/β (−/−)] mice is significantly reduced from levels seen in wild-type mice, whereas responses seen in IL-1Ra (−/−) mice are profoundly exacerbated or enhanced. These observations indicate that IL-1 plays important roles in the development of AHR and in establishing an important balance between proinflammatory cytokines and their inhibitors in allergic airway disease [33].

2.3. Experimental Application in Targeting the IL-1RI/IL-1 Pathway. Using the asthma animal model, the effects of targeting the IL-1RI/IL-1 pathway are summarized in Table 1. Reagents used include recombinant adenosine expressing human IL-1α (Ad-hIL-1ra), recombinant human interleukin-1 receptor antagonist (rhIL-1ra), and neutralizing antibodies to both IL-1β and IL-1α. Following airway sensitization with ovalbumin, there is suppression of AHR, inflammatory infiltration, and IL-5 production after antigen challenge in mice expressing the IL-1Ra adenosine [34]. Using guinea pigs sensitized with different allergens, two


### Table 1: Effect of therapeutic experiments Targeting IL-1RI/IL-1 pathway.

| Reagent | Mechanism | Animal model | airway hyper-reactivity (AHR) | Inflammatory infiltration (eosinophils and lymphocytes) | IgE | Th1 cytokine | Th2 cytokine | Ref |
|---------|-----------|--------------|-------------------------------|----------------------------------------------------------|-----|-------------|-------------|-----|
| Recombinant adenovirus expressing human IL-1ra (Ad-hIL-1ra) | receptor antagonist; gene therapy | Mice sensitized with ovalbumin (OVA)-immunized mice | ↓ | ↓ | N.A. | ↓ (IFN-γ) | ↓ (IL-5) | [34] |
| Recombinant human interleukin-1 receptor antagonist (rhIL-1ra) | receptor antagonist | guinea pigs sensitized with Ascaris antigen | ↓ | ↓ | N.A. | N.A. | N.A. | [35] |
| Recombinant human interleukin-1 receptor antagonist (rhIL-1ra); antibodies against IL-1β | receptor antagonist | asthmatic guinea pigs sensitized with ovalbumin (OVA)-immunized mice | the asthmatic symptom was obviously attenuated | ↓ adhesion-Molecules (sICAM-1 and P-selectin) levels | N.A. | N.A. | N.A. | [36] |
| Antibodies against IL-1β | neutralizing monoclonal Ab | murine model of toluene diisocyanate-induced asthma | partial reduction | ↓ adhesion-Molecules (ICAM-1 and VCAM-1) levels | N.A. | N.A. | ↓ (IL-4) | [37] |

Studies using rhIL-1ra also demonstrate reduced airway symptoms induced by allergen challenge [35, 36]. Regarding the effect on inflammation, there is decreased expression of adhesion molecules only in one study [36]. In mice treated with neutralizing anti-IL-1β antibodies, AHR to inhaled antigen is partially reduced but with a concomitant decrease in the expression of other adhesion molecules, as well as the suppression of IL-4 [37].

### 3. ST2-IL-33

IL-33, another IL-1-like cytokine, drives the production of Th2-associated cytokines from in vitro polarized Th2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathologic changes in mucosal organs [13]. Mice injected with human IL-33 exhibit impressive pathologic changes in the arterial walls, lungs, and intestinal tissues [13]. Of particular relevance to the concept of IL-33-driven Th2 response is the prominent eosinophilic infiltration in lung tissue. Airway smooth muscle cells have IL-33 expression in both the protein and mRNA levels. IL-33 expression increases in bronchial biopsies in asthmatic subjects compared to controls, as well as subjects with severe asthma [38].

IL-33 mediates its biologic effects via ST2, an IL-1 receptor-related protein specifically expressed on mast cells and Th2 lymphocytes [15] that has been shown to function as an important effector molecule of Th2 responses in some experimental settings, including mouse asthma models. IL-33 administration induces AHR and goblet cell hyperplasia through the induction of IL-4, IL-5, and IL-13 entirely independent of the acquired immune system. Administration of IL-33 induces AHR and goblet cell hyperplasia in the lungs in the absence of an adaptive immune system [39]. It stimulates mast cells into producing IL-13 in an FcεRI-independent manner [40].

A prior study has shown ST2 to be highly expressed on Th2 cells and it appears to play a role in Th2 cell activation [41]. The ST2 gene is a member of the IL-1 receptor family, producing a secreted soluble form, soluble ST2 (sST2), and a transmembrane form, ST2L [42]. The structure of ST2L is similar to that of IL-1 receptor type 1 (IL-1RI), which consists of three extracellular immunoglobulin domains and an intracellular Toll/IL-1 receptor domain. Although the extracellular domain is common to sST2 and ST2L, sST2 lacks the trans-membrane and intracellular Toll-interleukin-1 receptor domains [15].

Beyond its role as a therapeutic target, sST2 has also emerged as a disease biomarker. Previous studies in human patients and animal models have shown that the level of sST2 in sera is elevated in asthma [43, 44]. Therefore, it is suggested that sST2 also plays a critical role in Th2 cell-mediated diseases. Administering a recombinant sST2-Fc fusion protein or a sST2 expression vector to asthmatic mice effectively attenuates inflammatory responses and
di to wild-type (WT) mice. This is associated with reduced ST2 (3.2. Studies in ST2/IL-33 Pathway-Deficient Mice. [49]. is a critical signal transducer in the IL-33 signaling pathway TLR adaptor molecules such as MyD88 [48], while TRAF6 MAPKs, induces Th2 cytokine expression, and leads to severe Binding of IL-33 to ST2 receptor activates NF-κB signaling, consistent with IL-33 receptor signaling via the recruitment of a coreceptor, IL-1RAcP [28]. IL-33 forms a heterodimer complex with ST2 and IL-1RAcP for signal transduction [46, 47]. Thus, IL-1RAcP represents a shared co-receptor within the IL-1 family that is essential for IL-33 signaling via T1/ST2, aside from the IL-1 signaling. Binding of IL-33 to ST2 receptor activates NF-κB and MAPKs, induces Th2 cytokine expression, and leads to severe pathologic changes in mucosal organs. ST2 can sequester TLR adaptor molecules such as MyD88 [48], while TRAF6 is a critical signal transducer in the IL-33 signaling pathway [49].

3.1. Signaling Pathway. The ST2 receptor is similar to the IL-1RI and IL-18Rα in that it is composed of three extracellular Ig domains and an intracellular Toll domain. T1/ST2-dependent IL-33 responses resemble classical IL-1-like signaling, consistent with IL-33 receptor signaling via the recruitment of a coreceptor, IL-1RAcP [28]. IL-33 forms a heterodimer complex with ST2 and IL-1RAcP for signal transduction [46, 47]. Thus, IL-1RAcP represents a shared co-receptor within the IL-1 family that is essential for IL-33 signaling via T1/ST2, aside from the IL-1 signaling. Binding of IL-33 to ST2 receptor activates NF-κB and MAPKs, induces Th2 cytokine expression, and leads to severe pathologic changes in mucosal organs. ST2 can sequester TLR adaptor molecules such as MyD88 [48], while TRAF6 is a critical signal transducer in the IL-33 signaling pathway [49].

3.2. Studies in ST2/IL-33 Pathway-Deficient Mice. ST2 (−/−) mice develop reduced allergic airway inflammation compared to wild-type (WT) mice. This is associated with reduced differentiation of IL-5+ T cells. However, IL-4 and IL-13 levels are similar in WT and ST2 (−/−) mice. There is a less pronounced increase in total cell, macrophage, and eosinophil accumulation in the BAL fluids of ST2 (−/−) mice compared to WT mice [50]. These indicate that IL-33/ST2 signaling is an important pathway in allergic airway inflammation. IL-33 may be involved in lung macrophage activation in clinical asthma and may play a significant role in the amplification of alternatively activated macrophage (AAM) polarization and chemokine production, which contribute to both innate and Ag-induced airway inflammation [51]. Using a primary pulmonary granuloma model induced with Schistosoma mansoni eggs, Townsend et al. have demonstrated that granuloma formation, characterized by eosinophil infiltration, is abrogated in T1/ST2-deficient mice [52]. Naive immune cell populations, cytokine levels, Th1 and Th2 cell development, and total Ig isotype production are normal in T1/ST2-deficient mice. In the absence of T1/ST2-expression, induction of primary synchronous pulmonary granuloma formation and Th2 cytokine (IL-4 and IL-5) production occurs in response to the formation of secondary pulmonary granuloma. Such data demonstrates clearly that T1/ST2 expression plays a role in the development of Th2-like cytokine responses.

3.3. Experimental Application in Targeting the ST2/IL-33 Pathway. Using the asthma animal model, the effects of targeting the ST2/IL-33 pathway is summarized in Table 2. Reagents used include neutralizing antibodies against IL-33, neutralizing antibodies against T1/ST2, recombinant sST2, and recombinant ST2-expressing plasmid. Treatment with anti-IL-33 significantly reduces serum IgE secretion, the number of eosinophils and lymphocytes, and concentrations of IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid compared to administering a control antibody, which indicate that blocking IL-33 may be a new therapeutic strategy for allergic asthma [53]. Blocking IL-33–T1/ST2 signaling using an antibody against T1/ST2 abrogates persistent AHR, suggesting that the IL-33–T1/ST2 pathway is necessary not only in the development of an allergic response but also for its maintenance. Anti-T1/ST2 antibody also significantly reduces the expression of IL-4. In contrast, IL-13 levels are unchanged [54]. In a murine model of asthma, pretreatment with sST2 reduces IL-4, IL-5, and IL-13 production from IL-33-stimulated splenocytes [42]. This indicates that sST2 acts as a negative regulator of Th2 cytokine production and allergic airway inflammation modulates the biological activity of IL-33 signaling. Soluble ST2 directly binds to IL-33 and suppresses the activation of NF-κB in EL-4 cells stably expressing ST2L, suggesting that the complex of sST2 and IL-33 fails to bind to ST2L. Enhanced expression levels of sST2 are also achieved by intravenous gene transfer, resulting in a

| Table 2: Effect of therapeutic experiments Targeting ST-2/IL-33 pathway. |
|-------------------|-------------------|------------------|------------------|------------------|-------------------|-------------------|
| **Reagent**       | **Mechanism**     | **Animal model** | **airway hyper-reactivity (AHR)** | **Inflammatory infiltration (eosinophils and lymphocytes)** | **Th1 cytokine** | **Th2 cytokine** | **Ref**          |
| antibodies against IL-33 | neutralizing monoclonal Ab | Mice sensitized with ovalbumin | N.A. | ↓ | ↓ | ↓ (IL-4, IL-5, and IL-13) | [53] |
| antibodies against T1/ST2 | blocking monoclonal | Mice sensitized with ovalbumin | N.A. | N.A. | N.A. | ↓ (IL-4); N.A. | [54] |
| recombinant soluble ST2 protein | soluble receptor | Mice sensitized with ovalbumin; OVA-stimulated splenocytes | N.A. | N.A. | N.A. | ↑ (IFN-γ) from stimulated splenocytes | [42] |
| plasmid expressing soluble ST2 | gene therapy | Mice sensitized with ovalbumin | N.A. | ↓ (eosinophils) | N.A. | ↑ (IFN-γ) | (IL-4 and IL-5) | [44] |

 decreases Th2 cytokine production [45]. These therapeutic experiments indicate that sST2 negatively regulates Th2 cell-mediated immunologic responses, as opposed to ST2L.
drastic reduction in the number of eosinophils and in IL-4 and IL-5 levels in BAL fluid [44].

4. Conclusions and Future Perspectives

Collectively, the IL-1RI—IL-1 and T1/ST2—IL-33 pathways are critical for immunologic control of allergic inflammation (Figure 1). From asthma animal studies, emerging strategies for asthma treatment are aimed at restoring the imbalance in cytokine (IL-1 and IL-33) and signaling pathways (IL-1RI and ST2) that mediate inflammatory and structural changes, and in skewing the cytokine profile away from a pro-inflammatory response towards a regulatory response. Potential therapeutic approaches may identify new strategies targeting key molecular mediators that drive inflammatory responses in asthmatic lungs. Such strategies include the depletion of cytokines using neutralizing mAb and soluble receptor constructs, receptor blocking via binding to recombinant receptor antagonists, small-molecule receptor antagonists or neutralizing mAb [55], and target receptors or cellular signal transduction pathways that are activated following cytokine receptor ligation, and gene therapy (expressing receptor antagonists or soluble receptor). Such approaches provide disease-modifying treatments.

Recently, there has been much focus on the signaling pathways involved in asthma. Among these, the MAPK pathway members JNK and p38 have attracted much interest, aside from NF-κB, AP-1, and signal transducer and activator of transcription (STAT)-6 [56]. These signaling pathways are all involved in the IL-1RI—IL-1 and T1/ST2—IL-33 pathways. With advances in knowledge of cellular and molecular mediators involved in inflammation underlying asthma, there is much promise the future development of potential new therapeutics.

References

[1] Q. Hamid and M. Tulic, “Immunobiology of asthma,” Annual Review of Physiology, vol. 71, pp. 489–507, 2009.
[2] Y.-H. Chuang, Y.-H. Yang, S.-J. Wu, and B.-L. Chiang, “Gene therapy for allergic diseases,” Current Gene Therapy, vol. 9, no. 3, pp. 185–191, 2009.
[3] M. Larché, D. S. Robinson, and A. B. Kay, “The role of T lymphocytes in the pathogenesis of asthma,” Journal of Allergy and Clinical Immunology, vol. 111, no. 3, pp. 450–463, 2003.
[4] A. W. Mould, A. J. Ramsay, K. I. Matthaei, I. G. Young, M. E. Rothenberg, and P. S. Foster, “The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity,” Journal of Immunology, vol. 164, no. 4, pp. 2142–2150, 2000.
[5] J. Bousquet, P. K. Jeffery, W. W. Busse, M. Johnson, and A. M. Vignola, “Asthma: from bronchoconstriction to airways inflammation and remodeling,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 5, pp. 1720–1745, 2000.
[6] J. H. T. Bates, M. Rincon, and C. G. Irvin, “Animal models of asthma,” American Journal of Physiology, vol. 297, no. 3, pp. L401–L410, 2009.
[7] C. M. Lloyd, J.-A. Gonzalo, A. J. Coyle, and J.-C. Gutierrez-Ramos, “Mouse models of allergic airway disease,” Advances in Immunology, vol. 77, pp. 263–295, 2001.
[8] M. Kool, T. Soullié, M. van Nimwegen et al., “Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells,” Journal of Experimental Medicine, vol. 205, no. 4, pp. 869–882, 2008.
[9] C. A. Dinarello, “Immunological and inflammatory functions of the interleukin-1 family,” Annual Review of Immunology, vol. 27, pp. 519–550, 2009.

[10] A. Mantovani, C. Garlanda, M. Locati et al., “Regulatory pathways in inflammation,” Autoimmunity Reviews, vol. 7, no. 1, pp. 8–11, 2007.

[11] L. A. J. O’Neill, “The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress,” Immunological Reviews, vol. 226, no. 1, pp. 10–18, 2008.

[12] S. Tominaga, “A putative protein of a growth specific cDNA from BALB/c–3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor,” FEBS Letters, vol. 258, no. 2, pp. 301–304, 1989.

[13] J. Schmitz, A. Owyang, E. Oldham et al., “IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines,” Immunity, vol. 23, no. 5, pp. 479–490, 2005.

[14] V. Trajkovic, M. J. Sweet, and D. Xu, “T1/T2AN—an IL-1 receptor-like modulator of immune responses,” Cytokine and Growth Factor Reviews, vol. 15, no. 2-3, pp. 87–95, 2004.

[15] R. Kakkar and R. T. Lee, “The IL-33/ST2 pathway: therapeutic target and novel biomarker,” Nature Reviews Drug Discovery, vol. 7, no. 10, pp. 827–840, 2008.

[16] J. E. Sims, C. J. March, D. Cosman et al., “cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily,” Science, vol. 241, no. 4865, pp. 585–589, 1988.

[17] S. K. Dower, S. R. Kronheim, and C. J. March, “Detection and characterization of high affinity plasma membrane receptors for human interleukin-1,” Journal of Experimental Medicine, vol. 162, no. 2, pp. 501–515, 1985.

[18] J. E. Sims, C. J. March, D. Cosman et al., “cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily,” Science, vol. 241, no. 4865, pp. 585–589, 1988.

[19] K. Kuno and K. Matsushima, “The IL-1 receptor signaling pathway,” Journal of Leukocyte Biology, vol. 56, no. 5, pp. 542–547, 1994.

[20] J. L. Slack, K. Schooler, T. P. Bonnert et al., “Identification of two major sites in the type I interleukin-1 receptor cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways,” The Journal of Biological Chemistry, vol. 275, no. 7, pp. 4670–4678, 2000.

[21] A. Dunne and L. A. O’Neill, “The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense,” Science’s STKE, vol. 2003, no. 171, p. re3, 2003.

[22] S. A. Greenfeder, P. Nunes, L. Kwee, M. Labow, R. A. Chizonite, and G. Ju, “Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex,” The Journal of Biological Chemistry, vol. 270, no. 23, pp. 13757–13765, 1995.

[23] S. P. Eisenberg, M. T. Brewer, E. Verderber, P. Heimdal, B. J. Brandhuber, and R. C. Thompson, “Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 12, pp. 5232–5236, 1991.

[24] N. J. Gay and F. J. Keith, “Drosophila Toll and IL-1 receptor,” Nature, vol. 351, no. 6325, pp. 355–356, 1991.

[25] L. A. J. O’Neill and C. Greene, “Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants,” Journal of Leukocyte Biology, vol. 63, no. 6, pp. 650–657, 1998.

[26] G. P. A. Vigers, L. J. Anderson, P. Caffes, and B. J. Brandhuber, “Crystal structure of the type-I interleukin-1 receptor complex with interleukin-1β,” Nature, vol. 386, no. 6621, pp. 190–194, 1997.

[27] H. Schreuder, C. Tardif, S. Trump-Kallmeyer et al., “A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist,” Nature, vol. 386, no. 6621, pp. 194–200, 1997.

[28] W. P. Arend, G. Palmer, and C. Gabay, “IL-1, IL-18, and IL-33 families of cytokines,” Immunological Reviews, vol. 223, no. 1, pp. 20–38, 2008.

[29] F. Bureau, S. Delhalle, G. Bonizzi et al., “Mechanisms of persistent NF-κB activity in the bronchi of an animal model of asthma,” Journal of Immunology, vol. 165, no. 10, pp. 5822–5830, 2000.

[30] W. A. Wuyts, B. M. Vanauwenaerde, L. J. Dupont, M. G. Demedics, and G. M. Verleden, “Involvement of p38 MAPK, JNK, p42/p44 ERK and NF-κB in IL-1β-induced chemokine release in human airway smooth muscle cells,” Respiratory Medicine, vol. 97, no. 7, pp. 811–817, 2003.

[31] N. Schmitz, M. Kurrer, and M. Kopf, “The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model,” European Journal of Immunology, vol. 33, no. 4, pp. 991–1000, 2003.

[32] S. Nakae, Y. Komiyama, H. Yokoyama et al., “IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response,” International Immunology, vol. 15, no. 4, pp. 483–490, 2003.

[33] I. Tillie-Leblond, J. Pugin, C.-H. Marquette et al., “Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 2, pp. 487–494, 1999.

[34] C.-C. Wang, C.-L. Fu, Y.-H. Yang et al., “Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma,” Gene Therapy, vol. 13, no. 19, pp. 1414–1421, 2006.

[35] S. Okada, H. Inoue, K. Yamauchi et al., “Potential role of interleukin-1 in allergen-induced late asthmatic reactions in guinea pigs: suppressive effect of interleukin-1 receptor antagonist on late asthmatic reaction,” Journal of Allergy and Clinical Immunology, vol. 95, no. 6, pp. 1236–1245, 1995.

[36] T. Li, W.-L. Lu, H.-Y. Hong et al., “Pharmacokinetics and anti-asthmatic potential of non-parenterally administered recombinant human interleukin-1 receptor antagonist in animal models,” Journal of Pharmacological Sciences, vol. 102, no. 3, pp. 321–330, 2006.

[37] V. J. Johnson, B. Yucesoy, and M. I. Luster, “Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma,” Journal of Allergy and Clinical Immunology, vol. 116, no. 4, pp. 851–858, 2005.

[38] D. Préfontaine, S. Lajoie-Kadoch, S. Foley, et al., “Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells,” Journal of Immunology, vol. 183, no. 8, pp. 5094–5103, 2009.

[39] Y. Kondo, T. Yoshimoto, K. Yasuda et al., “Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system,” International Immunology, vol. 20, no. 6, pp. 791–800, 2008.

[40] L. H. Ho, T. Ohno, K. Oboki et al., “IL-33 induces IL-13 production by mouse mast cells independently of IgE-FceRI...
Mediators of Inflammation

signals,” *Journal of Leukocyte Biology*, vol. 82, no. 6, pp. 1481–1490, 2007.

[41] W. A. Verri Jr., A. T. G. Guerrero, S. Y. Fukada et al., “IL-33 mediates antigen-induced cutaneous and articular hypersensitivity in mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 7, pp. 2723–2728, 2008.

[42] H. Hayakawa, M. Hayakawa, A. Kume, and S.-I. Tominaga, “Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation,” *The Journal of Biological Chemistry*, vol. 282, no. 36, pp. 26369–26380, 2007.

[43] K. Oshikawa, K. Kuroiwa, K. Tago et al., “Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation,” *American Journal of Respiratory and Critical Care Medicine*, vol. 164, no. 2, pp. 277–281, 2001.

[44] K. Oshikawa, K. Yanagisawa, S. Tominaga, and Y. Sugiyama, “Expression and function of the ST2 gene in a murine model of allergic airway inflammation,” *Clinical and Experimental Allergy*, vol. 32, no. 10, pp. 1520–1526, 2002.

[45] M. Löhnning, A. Stroehmann, A. J. Coyle et al., “T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 12, pp. 6930–6935, 1998.

[46] S. Ali, M. Huber, C. Kollewe, S. C. Bischoff, W. Falk, and M. U. Martin, “IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 47, pp. 18660–18665, 2007.

[47] A. A. Chackerian, E. R. Oldham, E. E. Murphy, J. Schmitz, S. Pflanz, and R. A. Kastelain, “IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex,” *Journal of Immunology*, vol. 179, no. 4, pp. 2551–2555, 2007.

[48] M. Gadina and C. A. Jefferies, “IL-33: a sheep in wolf’s clothing?” *Science’s STKE*, vol. 2007, no. 390, p. pe31, 2007.

[49] M. Funakoshi-Tago, K. Tago, M. Hayakawa et al., “TRAF6 is a critical signal transducer in IL-33 signaling pathway,” *Cellular Signalling*, vol. 20, no. 9, pp. 1679–1686, 2008.

[50] M. Kurowska-Stolarska, P. Kewin, G. Murphy et al., “IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4,” *Journal of Immunology*, vol. 181, no. 7, pp. 4780–4790, 2008.

[51] M. Kurowska-Stolarska, B. Stolarski, and P. Kewin, “IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation,” *Journal of Immunology*, vol. 183, no. 10, pp. 6469–6477, 2009.

[52] M. J. Townsend, P. G. Fallon, D. J. Matthews, H. E. Jolin, and A. N. J. McKenzie, “T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses,” *Journal of Experimental Medicine*, vol. 191, no. 6, pp. 1069–1075, 2000.

[53] X. Liu, M. Li, Y. Wu, Y. Zhou, L. Zeng, and T. Huang, “Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma,” *Biochemical and Biophysical Research Communications*, vol. 386, no. 1, pp. 181–185, 2009.

[54] J. Kearley, K. F. Buckland, S. A. Mathie, and C. M. Lloyd, “Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway,” *American Journal of Respiratory and Critical Care Medicine*, vol. 179, no. 9, pp. 772–781, 2009.

[55] C. Quiniou, P. Sapieha, I. Lahaie et al., “Development of a novel noncompetitive antagonist of IL-1 receptor,” *Journal of Immunology*, vol. 180, no. 10, pp. 6977–6987, 2008.

[56] K. Blease, A. Lewis, and H. K. Raymon, “Emerging treatments for asthma,” *Expert Opinion on Emerging Drugs*, vol. 8, no. 1, pp. 71–81, 2003.